Receipt date: 09/21/2006

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10597719
	Filing Date		
	First Named Inventor	Shah	, et al.
	Art Unit		1638
	Examiner Name		-
	Attorney Docket Number	er	70397

				U.S	.PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	of cited Document			es,Columns,Lines where evant Passages or Relevant ures Appear		
	1									
If you wish to add additional U.S. Patent citation information please click the Add button.							Add			
			U.S.P	ATENT APPL	ICATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		of cited Document		s,Columns,Lines where vant Passages or Relevant es Appear		
	1									
If you wis	h to ac	dd additional U.S. Publi	shed Ap	plication citati	on information	please click the Add	d button	Add		
FOREIGN PATENT DOCUMENTS Remove										
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication Date	Applicant of cited Passage		vhere Rele	or Relevant	T5
	1	02077157	wo		2002-10-03	Syngenta Participations AG				
	2	05069859	WO		2005-08-04	University of Utah Research Foundation				
If you wis	h to ac	⊥ dd additional Foreign P	ı atent Do	cument citatio	_l n information p	⊥ lease click the Add	button	Add		
			NON	I-PATENT LIT	ERATURE DO	CUMENTS		Remove		

Receipt date: 09/21/2006 INFORMATION DISCLOSURE STATEMENT BY APPLICANT		e: 09/21/2006	Application Number		10597719 1(1597719 - GAU: 1	1633
			Filing Date				
			First Named Inventor	Shal	h, et al.		
			Art Unit	1638			
(Not for	subm	ission under 37 CFR 1.99)	Examiner Name		1		
			Attorney Docket Number 70397				
			-				
Examiner Initials*	Cite No	Include name of the author (in (book, magazine, journal, ser	ial, symposium, catalog, e				T5
IIIIIIais	INO	publisher, city and/or country	where published.				
	1	KOZLOVA, TATIANA, ET AL: "N Vivo"; Methods in Enzymology, p			Nuclear Receptor Activa	ation and Function In	
	2	ROIGNANT, JEAN-YVES, ET A Specific RNAi in Drosophila"; pp				ell-specific and Isoform-	
	3	LAM, GEANETTE, ET AL: "Indu Drosophila"; Current Biology 200			ed RNA directs specific g	enetic interference in	
If you wis	h to a	। dd additional non-patent literatu	ure document citation infor	matio	n please click the Add	button Add	
			EXAMINER SIGNA	TURE		<u> </u>	
Examiner	Signa	ture /Kelaginamane Hiri	vanna/ (04/23/2010)		Date Considered	04/23/2010	
*EXAMIN		itial if reference considered, w	TOTAL PROPERTY OF THE PARTY OF				

Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

Receipt date: 09/21/2006 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10597719	10597719 - GAU: 1633	
	Filing Date				
	First Named Inventor	Shah	h, et al.		
	Art Unit		1638		
	Examiner Name				
	Attorney Docket Number		70397		

CERTIFICATION STATEMENT							
ase see 37 CFR 1	1.97 and 1.98 to make the app	propriate selection	on(s):				
That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).							
1							
foreign patent of after making rea any individual d	office in a counterpart foreign asonable inquiry, no item of in lesignated in 37 CFR 1.56(c	application, an	d, to the knowledge of the ined in the information di	ne person signing the certification isclosure statement was known to			
See attached ce	ertification statement.						
Fee set forth in	37 CFR 1.17 (p) has been sub	bmitted herewith	l.				
✓ None							
SIGNATURE A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.							
Signature /REBECCA GEGICK/ Date (YYYY-MM-DD) 2006-09-21							
ne/Print	Rebecca Gegick	Registration Number		51724			
	That each item from a foreign pinformation discontinuous d	That each item of information contained in a from a foreign patent office in a counterpart information disclosure statement. See 37 CFI That no item of information contained in the foreign patent office in a counterpart foreign after making reasonable inquiry, no item of in any individual designated in 37 CFR 1.56(c) statement. See 37 CFR 1.97(e)(2). See attached certification statement. Fee set forth in 37 CFR 1.17 (p) has been sure of the signature. In a counterpart foreign after making reasonable inquiry, no item of item any individual designated in 37 CFR 1.56(c) statement. See 37 CFR 1.97(e)(2).	That each item of information contained in the information of from a foreign patent office in a counterpart foreign application information disclosure statement. See 37 CFR 1.97(e)(1). That no item of information contained in the information difforeign patent office in a counterpart foreign application, an after making reasonable inquiry, no item of information contained in 37 CFR 1.56(c) more than the statement. See 37 CFR 1.97(e)(2). See attached certification statement. Fee set forth in 37 CFR 1.17 (p) has been submitted herewith None SIGNAT SIGNAT (REBECCA GEGICK) ne/Print Rebecca Gegick se collection of information is required by 37 CFR 1.97 and 1.98	That each item of information contained in the information disclosure statement was from a foreign patent office in a counterpart foreign application not more than three information disclosure statement. See 37 CFR 1.97(e)(1). That no item of information contained in the information disclosure statement was foreign patent office in a counterpart foreign application, and, to the knowledge of the after making reasonable inquiry, no item of information contained in the information dany individual designated in 37 CFR 1.56(c) more than three months prior to the firstatement. See 37 CFR 1.97(e)(2). See attached certification statement. Fee set forth in 37 CFR 1.17 (p) has been submitted herewith. None SIGNATURE signature of the applicant or representative is required in accordance with CFR 1.33, 10. In of the signature. Date (YYYY-MM-DD)			

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.